Induced pluripotent stem cells (IPS cells), generated by transcription factor-dependent nuclear reprogramming of differentiated somatic cells, are pluripotent stem cell lines that can be propagated indefinitely in culture and maintain the potential to differentiate into any cell type in the body. As iPS cells retain the same genetic make-up as the somatic cell targeted for reprogramming, these cells hold tremendous promise for uncovering novel genetic and biochemical factors that underiie diseases with complex and pooriy understood genetic influences, such as diabetes. The DRC iPS Core will establish and maintain a centralized facility for the reliable and consistent generation and propagation of reprogrammed IPS cells for use in cutting-edge research into the molecular and cellular pathologies underiying diabetes and its complications. The Core will enhance the scientific productivity of DRC projects in multiple ways: (1) By standardizing medical assessments and data collection from human subjects, as well as cell isolation protocols and reagents, the Core will allow direct comparison of data across projects and remove variability resulting from potential technical or biological differences in patient populations or cell handling. (2) As IPS cell production and propagation can be technically challenging, the Core will ensure reproducibility and comparability of results, by enforcing rigorous standards of quality control. (3) The Core will provide advanced training for investigators desiring to introduce IPS technologies into their own laboratories, increasing the currently small number of laboratories in the Boston area skilled in the isolation and culture of IPS cells. (4) The Core will provide expert advice on experimental design, regulatory documentation and interpretation of results, based on the extensive expertise of the Core Directors and Staff. (5) As the Core will be utilized by multiple labs, it will provide a venue for scientific interaction, fostering greater exchange of information among DRC Investigators and promoting productive collaborations with other Boston-based research groups. (6) The Core will help to develop new technologies that support center activities, including most notably the optimization of methods for deriving iPS cells from people with diabetes and the integration of new reprogramming technologies, including integration-free IPS generation and generation ofiPS cells from peripheral blood samples, as these become robust and available. These activities will benefit DRC Investigators and significantly accelerate advances in diabetes research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK036836-28
Application #
8725127
Study Section
Special Emphasis Panel (ZDK1-GRB-S)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
28
Fiscal Year
2014
Total Cost
$182,281
Indirect Cost
$62,950
Name
Joslin Diabetes Center
Department
Type
DUNS #
071723084
City
Boston
State
MA
Country
United States
Zip Code
02215
Pavkov, Meda E; Nelson, Robert G; Knowler, William C et al. (2015) Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87:812-9
Avadhani, Radhika; Fowler, Kristen; Barbato, Corinne et al. (2015) Glycemia and cognitive function in metabolic syndrome and coronary heart disease. Am J Med 128:46-55
Baskaran, Charumathi; Volkening, Lisa K; Diaz, Monica et al. (2015) A decade of temporal trends in overweight/obesity in youth with type 1 diabetes after the Diabetes Control and Complications Trial. Pediatr Diabetes 16:263-70
Rasbach, Lisa; Jenkins, Carolyn; Laffel, Lori (2015) An integrative review of self-efficacy measurement instruments in youth with type 1 diabetes. Diabetes Educ 41:43-58
Markowitz, Jessica T; Volkening, Lisa K; Laffel, Lori M B (2014) Care utilization in a pediatric diabetes clinic: cancellations, parental attendance, and mental health appointments. J Pediatr 164:1384-9
Castiglioni, Alessandra; Hettmer, Simone; Lynes, Matthew D et al. (2014) Isolation of progenitors that exhibit myogenic/osteogenic bipotency in vitro by fluorescence-activated cell sorting from human fetal muscle. Stem Cell Reports 2:92-106
Teo, Adrian Kee Keong; Valdez, Ivan Achel; Dirice, Ercument et al. (2014) Comparable generation of activin-induced definitive endoderm via additive Wnt or BMP signaling in absence of serum. Stem Cell Reports 3:5-14
Isganaitis, Elvira; Woo, Melissa; Ma, Huijuan et al. (2014) Developmental programming by maternal insulin resistance: hyperinsulinemia, glucose intolerance, and dysregulated lipid metabolism in male offspring of insulin-resistant mice. Diabetes 63:688-700
Sanders, Kaitlyn; Jung, Jin Hyuk; Loeken, Mary R (2014) Use of a murine embryonic stem cell line that is sensitive to high glucose environment to model neural tube development in diabetic pregnancy. Birth Defects Res A Clin Mol Teratol 100:584-91
Lee, Hyung-Yul; Wei, Dan; Loeken, Mary R (2014) Lack of metformin effect on mouse embryo AMPK activity: implications for metformin treatment during pregnancy. Diabetes Metab Res Rev 30:23-30

Showing the most recent 10 out of 706 publications